How to Prepare Strong BEP & BER
A comprehensive guide to developing risk-based, science-driven Biological Evaluation Plans and Reports that meet modern regulatory expectations.
Preparing strong Biological Evaluation Plans (BEP) and Biological Evaluation Reports (BER) is essential for successful medical device approvals. Regulatory authorities such as the US FDA and EU Notified Bodies closely examine these documents to confirm that biocompatibility risks have been properly identified, evaluated and controlled.
With the implementation of ISO 10993-1:2025, expectations for BEP and BER quality have increased significantly. Regulators now expect a risk-based, science-driven and well-documented approach rather than a simple list of tests. In this blog, Accuprec Research Labs Pvt. Ltd. explains how to prepare strong BEP and BER documents that meet current regulatory expectations.
The BEP and BER work together as part of a complete biocompatibility strategy:
- BEP defines the planned biological evaluation approach
- BER evaluates and concludes biological safety based on collected data
Consistency and alignment between these documents are critical for regulatory acceptance.
Start with Risk Management
ISO 10993-1:2025 requires close integration with ISO 14971 risk management. To prepare strong BEP and BER:
- Identify biological hazards early
- Link hazards to materials and patient exposure
- Define risk control measures
- Evaluate residual risks
Both BEP and BER should clearly reference the risk management file.
Clearly Define Device Use and Contact
Accurate device description is the foundation of biocompatibility assessment. Ensure that the BEP and BER clearly define:
- Intended use and indications
- Target patient population
- Nature of body contact
- Duration of contact
Incorrect or vague descriptions often lead to regulatory questions.
Understand Materials and Manufacturing Processes
A thorough understanding of materials and processes helps identify potential biological risks. Document details such as:
- Raw materials and additives
- Coatings and colorants
- Manufacturing aids
- Sterilization methods
This information supports hazard identification and chemical evaluation.
Use Chemical Characterization as a Foundation
Modern biocompatibility evaluation relies heavily on chemical characterization. A strong BEP should describe planned extractables and leachables studies, analytical techniques, and the use of chemical data in risk assessment. The BER should then evaluate these results and their safety impact.
Apply Toxicological Risk Assessment
Under ISO 10993-17, toxicological risk assessment is used to assess patient exposure to chemicals, compare exposure levels to safe limits, and determine acceptability of risk. Clearly summarizing toxicological conclusions in the BER strengthens regulatory confidence.
Justify Biological Testing
Testing should only be performed when scientifically justified. In the BEP, explain why a test is needed and justify why alternatives are insufficient. In the BER, evaluate test results critically and address any unexpected findings. Unjustified testing or poor interpretation is a common deficiency.
Leverage Existing and Clinical Data
ISO 10993-1:2025 encourages the use of existing data, including previous biocompatibility studies, clinical data, post-market surveillance, and published literature. Strong justification for data relevance can reduce new testing.
Maintain Consistency and Traceability
Regulators expect clear traceability between risk management documents, BEP decisions, and BER conclusions. Inconsistencies often trigger regulatory questions.
Write Clear, Structured and Reviewer-Friendly Documents
Strong BEP and BER documents are well-organized, easy to follow, scientifically justified, and device-specific. Avoid generic language or copy-paste content from other devices.
Regulatory reviewers often raise concerns when:
- BEP and BER are not aligned
- Risk management linkage is missing
- Chemical characterization is ignored
- Toxicological rationale is weak
- Conclusions are unclear
Avoiding these mistakes improves approval success.
High-quality BEP and BER documents result in:
- Faster regulatory reviews
- Fewer deficiency letters
- Reduced testing costs
- Improved patient safety assurance
They also support lifecycle management and design changes.
Accuprec Research Labs Pvt. Ltd. supports manufacturers by providing:
- ISO 10993-1:2025–aligned BEP and BER preparation
- Risk-based biocompatibility strategies
- Chemical characterization and toxicology support
- Regulatory-ready documentation for global submissions
Our expertise helps ensure accuracy, compliance and confidence.
Preparing strong BEP and BER documents is essential for modern medical device development. Under ISO 10993-1:2025, these documents must be risk-based, science-driven and clearly justified.
Manufacturers who invest in robust BEP and BER preparation are better positioned for smooth regulatory reviews and successful global approvals.
